^
    Back
    Association details:
    Biomarker:CEACAM5 expression
    Cancer:Solid Tumor
    Drug:tusamitamab ravtansine (SAR408701) (Microtubule inhibitor, CEACAM5-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Tusamitamab ravtansine in NSQ NSCLC participants with negative or moderate CEACAM5 expression tumors and high circulating CEA

    Excerpt:
    ...- Histologically or cytologically proven diagnosis of NSQ NSCLC metastatic disease at study entry; progression after platinum-based chemotherapy and immune checkpoint inhibitor.- Participants with moderate or negative CEACAM5 expression as demonstrated prospectively by central laboratory via immune histochemistry (ICH) and high circulating CEA levels (≥100 ng/mL). ...
    Trial ID:
    2021-004423-32
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA

    Excerpt:
    ...- Participants with moderate or negative CEACAM5 expression as demonstrated prospectively by central laboratory via immune histochemistry (ICH) and high circulating CEA levels (≥100 ng/mL)....
    Trial ID:
    CARMEN-LC06
    More C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Res Commun
    Title:

    Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

    Published date:
    08/28/2023
    Excerpt:
    Adults ages ≥18 years (range, 34-73) with locally advanced/metastatic solid tumors (N = 43...expressing/likely to express CEACAM5 received intravenous tusamitamab ravtansine...stable disease occurred in 35.7% of patients in Q2W-LD and 40.0% of patients in Q3W.
    DOI:
    10.1158/2767-9764.CRC-23-0284
    Trial ID:
    CEACAM5